Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06793371 · ClinicalTrials.gov registry record · Phase 2
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
A Phase 2 study of Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF), sponsored by Cytokinetics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 20
- Study locations
NCT06793371 is a Phase 2 study of Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) that is actively recruiting participants, run by Cytokinetics. The registered enrollment target is 60 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT06793371, a Phase 2 study of Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF), is actively recruiting participants, sponsored by Cytokinetics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2 dose-finding study in adult participants with symptomatic HFpEF.
Conditions Studied
Interventions
- DRUG CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)
- DRUG Placebo to match CK-4021586
Study Locations (20)
California
- BioSolutions Clinical Research Center - Imperial
- Profound Research LLC - Pasadena
- University of California, San Francisco - Heart and Vascular Center - San Francisco
- FOMAT - Comprehensive Cardiovascular Care - Santa Maria
- Blue Coast Research Center, LLC - Vista
Florida
- New Generation of Medical Research - Hialeah
- Cleveland Clinic Florida - Weston
Alabama
- Eastern Shore Research Institute, LLC - Fairhope
Arizona
- University of Arizona Sarver Heart Center - Tucson
Arkansas
- John L. McClellan Memorial Veterans Hospital - Little Rock
Illinois
- Methodist Medical Center of Illinois - Peoria
Louisiana
- Louisiana Heart Center - Slidell
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-02-06 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06793371
The ClinicalTrials.gov registry entry for NCT06793371 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cytokinetics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) appearing as the primary indexed condition, and to 2 interventions - of which CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg) is the first listed.
NCT06793371 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT06793371 about?
NCT06793371 is a clinical study titled "AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF". This is a Phase 2 dose-finding study in adult participants with symptomatic HFpEF.
What is the current status of trial NCT06793371?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-02-06. Estimated completion is 2026-09.
What conditions does trial NCT06793371 study?
This clinical trial studies the following conditions: Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF).
What interventions are being tested in trial NCT06793371?
The interventions under investigation include: CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg) (DRUG), Placebo to match CK-4021586 (DRUG).
Who is sponsoring clinical trial NCT06793371?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06793371 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.